Bone Biologics sets date for 2025 annual meeting

Bone Biologics Corp (NASDAQ:BBLG), a micro-cap company currently valued at $2.75 million, has announced that its 2025 Annual Meeting of Stockholders is scheduled for May 30, 2025. According to InvestingPro data, the company’s stock has declined over 61% in the past six months, though current analysis suggests the stock may be undervalued. The decision was made by the company’s Board of Directors on March 26, 2025. This date represents a shift of more than 30 days prior to the anniversary of the company’s last annual meeting.

As a result of the new meeting date, the deadlines for shareholder proposals and director nominations as stated in the previous year’s proxy statement are no longer valid. Shareholders interested in submitting proposals or nominations must now adhere to the updated deadline of April 11, 2025. All submissions must comply with the SEC rules and the company’s amended and restated bylaws. The company maintains strong liquidity, with a current ratio of 10.22 and more cash than debt on its balance sheet, according to InvestingPro analysis.

The company, which operates within the orthopedic, prosthetic, and surgical appliances and supplies industry, has specified that any nominations or proposals should be directed to the Corporate Secretary at Bone Biologics Corporation’s headquarters in Burlington (NYSE:BURL), Massachusetts.

Details regarding the record date for the annual meeting and the proposals to be presented will be included in the Definitive Proxy Statement on Schedule 14A, which will be filed with the SEC. This document will provide shareholders with the necessary information to participate in the annual meeting process.

This announcement, based on a press release statement, is aimed at informing shareholders and the market about the upcoming annual meeting and the associated deadlines for active shareholder participation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.